VCA Stocks

AILERON Therapeutics, a biopharmaceutical company applying its proprietary Stapled Peptide technology to the development of breakthrough biologics for the treatment of cancer and other diseases, announced today that it has raised $10 million.  AILERON Therapeutics is a biopharmaceutical company based in Cambridge, MA that is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by current drug modalities. AILERON’s proprietary cell penetrating Stapled Peptide technology is being applied to generate breakthrough therapeutics for the treatment of cancer and other diseases. AILERON believes that Stapled Peptides have the potential to become a major new class of drugs for intracellular and extracellular targets across multiple therapeutic areas.